Podcasts about pesta

01062026 I'm Back LIVE Kate and Pesta Venezuela The Truth and The Narrative by Kate Dalley

Learn how to talk about having a party. - Mari belajar bagaimana bicara tentang rencana mengadakan pesta.

Dr. Duke Pesta is the founder and executive director of Freedom Project Academy. For the past 15 years, FPA has been providing a live, fully-accredited pre-K-12 online homeschooling platform to those seeking a classical education. In this in-depth conversation, Bill Jasper of The New American speaks with Pesta about his innovative approach and what sets it apart: real-time ... The post Freedom Project Academy: A Classical, Live-Online Alternative to Public Education appeared first on The New American.

Komisaris Kepolisian Kota New York, Jessica Tisch, Menyatakan Kepolisian New York Siap Mengamankan Pesta Pergantian Tahun dari 2025 ke 2026.

La pesta porcina en senglars no coincideix amb les mostres del CReSA

L'anàlisi encarregada per la Generalitat descarta que el virus de la pesta porcina sortís de l'IRTA-CReSA, segons la seqüència genètica investigada de les mostres. Conversem amb Juan José Badiola, Veterinari i epidemiòleg, Catedrátic Emèrit de Sanitat Animal de la Facultat de Veterinaria de la Universitat de Saragossa.

Dibawakan oleh Rini Sudarno dari Gereja Santo Ambrosius, Paroki Villa Melati Mas di Keuskupan Agung Jakarta, Indonesia. Sirakh 3: 2-6.12-14; Mazmur tg 128: 1-2.3.4-5; Kolose 3: 12-21; Matius 2: 13-15.19-23.KITA BERSAMA-SAMAMERAWAT KELUARGA Tema renungan kita pada hari Minggu, Pesta Keluarga Kudusini ialah: Kita Bersama-sama Merawat Keluarga. Sejak penciptaan, Tuhan menetapkan manusia untuk hidup berkeluarga, yangdimulai dengan saling mencintai antara pria dan wanita. Dari situ terbentuklahperkawinan dan keturunan-keturunan yang dihasilkannya.  Perintah Tuhan pertama dan utama bagi keluarga ialah pria mengambil wanita sebagaiistri dan mereka hidup dalam persekutuan satu daging. Satu pria dan satu wanitadipersatukan oleh Tuhan atas dasar cinta dan dalam nama Tuhan. Perintah lainyang sama pentingnya ialah perkawinan menghasilkan keturunan. Untuk suatu kelangsungan hidup perkawinan yang tetap utuh,kemudian anak-anak hasil perkawinan tumbuh sesuai dengan harapan, maka sangatdiperlukan sebuah disiplin hidup. Menurut bacaan-bacaan pada hari ini, disiplinhidup itu dapat kita sebut sebagai upaya kita bersama-sama untuk merawatkeluarga.  Tuhan membentuk keluarga tidak dengan satu orang saja,tetapi satu pria dan satu wanita ditambah dengan anak-anak yang masing-masingnyaunik. Mereka harus bekerja sama dalam membangun keluarga. Mereka bekerja samabukan hanya ketika keluarga di dalam keadaan gembira atau kemajuan di dalampertumbuhannya. Mereka diminta lebih kuat dalam persekutuan dan bekerja samanyaketika datang kesulitan dan ancaman yang membahayakan kehidupan keluarga. Keluarga yang gembira, damai dan bertumbuh dengan sehatperlu dirawat melalui hubungan orang tua dan anak-anak yang benar-benardikehendaki oleh Tuhan. Menurut kitab putra Sirakh, seorang manusia berimanyang takut akan Allah dan setia dengan perintah-perintah-Nya, ia harus wujudkanitu dengan taat kepada orang tuanya. Kita selalu percaya bahwa orang tua adalahwakil Tuhan di dunia. Cara kita merawat keluarga secara bersama-sama juga sesuaidengan nasihat Santo Paulus dalam bacaan kedua hari ini, yaitu mengisi danmenjalani kehidupan keluarga dengan cinta kasih. Keluarga itu diawali dengancinta suami dan istri, maka keluarga juga harus dibangun di dalam kasih, danakhirnya mewujudkan kasih yang sempurna, yaitu persekutuan dengan Tuhan. Kisah tentang Keluarga Nazareth yang menyingkir ke Mesirmerupakan contoh bagaimana kita merawat keluarga secara bersama-sama ketikakeluarga di dalam kesulitan, ancaman, dan dalam ambang bahaya. Kerja sama inibukan hanya di antara sesama anggota keluarga atau tetangga, tetapi juga dengankuasa Tuhan. Ketika Tuhan ikut terlibat, pekerjaan merawat keluarga akanmenjadi sangat bermutu dan ideal. Tuhan menolong ketika keluarga sedangmenderita. Marilah kita berdoa. Dalam nama Bapa... Ya Tuhan, semogaperayaan hari Minggu dan Pesta Keluarga Kudus ini dapat membantu membuatkeluarga-keluarga kami semakin beriman dan setia kepada-Mu. Salam Maria, penuhrahmat ... Dalam nama Bapa ...

Dibawakan oleh Oliva Ivania dan Hendrik Monteiro dari Komunitas Kongregasi Bunda Hati Tersuci Maria di Keuskupan Maumere, Indonesia. Kisah Para Rasul 6: 8-10; 7: 54-59; Mazmur tg 31: 3cd-4.6.8ab.16bc.17; Matius 10: 17-22.JALAN SALIBSETELAH NATAL Tema renungan kita pada hari ini ialah: Jalan SalibSetelah Natal. Pada hari ini kita merayakan pesta Santo Stefanus, seorang muridYesus yang istimewa dan martir pertama Gereja. Dia salah satu para diakon yangterpilih untuk melayani urusan-urusan jasmani komunitas Gereja Perdana,sementara para rasul fokus pada pelayanan sabda dan doa, seperti yangdikisahkan dalam Kisah Para Rasul. Dengan suatu kenangan peristiwa kemartiran pada hari keduasetelah Natal ini, inspirasi yang pas buat kita ialah semangat hidup di dalamRoh Kudus. Misteri inkarnasi dapat kita masuki, memahami dan mengimaninyakarena bantuan Roh Kudus. Yesus Kristus yang terbaring sebagai bayi dalampalungan tahu jelas nasib-Nya nanti di puncak Golgota. Kandang Bethlehemdihubungkan dengan bukit Golgota, di mana jalan itu akan mulai dilalui olehYesus, sang juru selamat. Jadi kaitan kedua simbol tempat ini sebenarnyamengungkapkan alasan utama mengapa Putra Allah, Sabda kekal itu, menjadimanusia untuk menebus umat manusia dari perbudakan dosa dan kematian. Hasilnyaialah kehidupan baru dianugerahkan bagi semua pengikut Yesus Kristus yangadalah putra-putri Bapa. Yesus sedari awal hidupnya sudah memberikan pelajaran,dan ia memastikan jalan hidup-Nya, bahwa jalan kepada Bapa ialah jalan salib.  Santo Stefanus sebagai yang pertama di dalam Gereja yangbaru saja berdiri di Yerusalem pada waktu itu, menikmati salib itu. Jika kitasemua memilih untuk berbagi di dalam kemuliaan Yesus Kristus, maka kita harusmemanggul salib kita setiap hari dan mengikuti Kristus melewati jalan yangtelah Ia lalui. Untuk memberikan semangat dan kekuatan kepada kita, Yesus terusterang saja berkata kepada para rasul, murid dan semua pengikut-Nya tentangrisiko dalam pilihan mengikuti Dia. Ini semua menjadi mungkin hanya di dalam terangdan bimbingan Roh Kudus. Pesan Natal sebenarnya berisi risiko sebagai para pengikutKristus itu. Yesus dari awal lahir-Nya memiliki risiko itu. Setiap orang yangdibaptis juga dibuat jelas tentang ini, bahwa risiko dan tujuan akhir darimengambil bagian dalam Kristus hanya akan dicapai melalui salib. Kemuliaan dankebahagiaan di dalam Kristus harus dibayar dahulu dengan suatu harga amatmahal, ialah pengorbanan diri dengan kematian, termasuk dalam cara mati demiKristus seperti yang dialami Santo Stefanus. Yesus berpesan bahwa Ia telah memberikan rahmat yangmemadai untuk setiap orang dalam memanggul salib dan membuat suatu pengorbanandalam hidup demi mendapatkan kemuliaan bersama Dia. Jadi tak akan ada salib,pengorbanan, dan penderitaan yang jelek atau hampa di dalam Kristus.Marilah kita berdoa. Dalam nama Bapa... Ya Tuhan YesusKristus, kuatkanlah kami selalu dengan rahmat-Mu supaya kami memanggul salibkami dengan gembira dan dalam pengharapan. Kemuliaan kepada Bapa dan Purta danRoh Kudus... Dalam nama Bapa...

Dibawakan oleh Oliva Ivania dan Hendrik Monteiro dari Komunitas Kongregasi Bunda Hati Tersuci Maria di Keuskupan Maumere, Indonesia. 1 Yohanes 1: 1-4; Mazmur tg 97: 1-2.5-6.11-12; Yohanes 20: 2-8.CINTA YANG DALAMDAN TAK BERAKHIR Tema renungan kita pada hari ini ialah: Cinta Yang DalamDan Tak Berakhir. Pada hari ini kita merayakan pesta Santo Yohanes, rasul danpengarang Injil. Injil bercerita bahwa Yohanes adalah adik rasul Yakobus yangdipanggil berdua oleh Yesus saat mereka bersama ayah Zebedeus sedang melaut diDanau Galilea. Yohanes selalu tampil bertiga Petrus dan Yakobus mendampingiYesus.  Masih dalam suasana Natal, selain kita diperkenalkanprofil salib sebagai cara untuk mengambil bagian di dalam Kristus dan nantinyamencapai kemuliaan, kita juga diperkenalkan untuk mencapai kemuliaan kerajaanAllah melalui cinta yang dalam dan tak berakhir. Kita dapat katakan bahwa cintasejati atau genuine love itu sangatdikaitkan dengan Santo Yohanes rasul. Alasan yang sangat mendasari ini ialahInjil yang ditulisnya berisi ajaran cinta kasih yang sangat mendalam. Misalnya,tentang roti hidup dan gembala yang baik, yang berisi ajaran cinta kasih yangamat dalam maknanya. Alasan lain yang ditunjukkan Injil hari ini ialah karenaia yang paling pertama dari kalangan rasul dan murid Yesus yang mengerti danpercaya akan kebangkitan Yesus. Cintanya kepada Yesus begitu mendalam, sehinggadalam keadaan yang sulit dan mencemaskan pun pemahaman dan imannya kepada Tuhantidak pernah berkurang. Kekhususan rasul Yohanes ini terungkap dalam InjilKeempat bahwa rasul ini adalah yang paling dikasihi Tuhan. Ini adalah suatu pandanganyang sangat kuat dan mengikat, karena ia sendiri yang menuliskan itu. Pendapat yang lebih dapat diterima bersama ialah bahwadengan satu pribadi yang sangat dikasihi oleh Tuhan namun tak dijelaskanidentitas persisnya, bermaksud untuk menunjukkan semua pengikut Kristus: entahrasul dan murid, entah pria dan wanita, entah orang muda dan dewasa, entah yangsekolah atau terdidik dan tidak, entah orang tua dan anak-anak, semua ituadalah pribadi-pribadi yang dikasihi Tuhan. Berarti, saya secara pribadidikasihi oleh Tuhan. Anda juga dikasih Tuhan secara pribadi. Dia mendapatkan jugakasih secara pribadi dari Tuhan. Setiap orang pada dasarnya berhak dikasihioleh Tuhan maha pengasih. Adalah sungguh indah mengalami kasih dari Tuhan yangdiberikan ke pribadi kita masing-masing, dicurahkan dengan sempurna, dijaminkualitasnya sampai selamanya, dan tak bersyarat apa pun. Yang penting kasih itudatang ke dalam hidup pribadi Anda dan saya. Ketika setiap orang dalam setiapkesadarannya mengakui dicintai seperti ini, ia sesungguhnya sedang mengalamikasih yang sejati. Di dalam masa Natal ini, kiranya kita berusaha untukmenerima kasih itu dari Tuhan lebih daripada biasanya, persis pada saat-saatbersama Yesus dan keluarga Nazareth yang hidup penuh dalam kasih. Marilah kita berdoa. Dalam nama Bapa... Ya Yesus Kristus dankeluarga Nazareth, kami ingin hidup dalam terang dan suasana keluarga-Mu yangtenang dan damai, maka anugerahkanlah kami rahmat ini ke dalamkeluarga-keluarga kami di dunia ini. Kemuliaan kepada Bapa dan Putra dan RohKudus ... Dalam nama Bapa ...

Renungan SeRoJa, Pesta Santo Yohanes, Rasul dan Penulis Injil, 27 Desember 2025

W wigilijnym Poranku Dwójki zabraliśmy Państwa do Wilna z okazji urodzin Adama Mickiewicza. O mieście młodości wieszcza opowiedział nasz litewski korespondent Kamil Zalewski

PESTO Trial Results: What Stroke Survivors Need to Know About Perispinal Etanercept If you've spent any time in stroke recovery communities, you've probably seen the same pattern: a treatment gets talked about with real intensity, people share personal stories that pull you in, and suddenly you're left trying to sort hope from hype from “maybe.” When the decision also involves significant cost, that uncertainty can feel even heavier. That's exactly why I recorded this episode: to help stroke survivors and their families understand the PESTO trial results in plain language without drama, without attacks, and without jumping to conclusions. In this interview, Professor Vincent Thijs explains what the PESTO trial set out to test, why it was designed the way it was, and what the results can (and can't) tell us about perispinal etanercept in stroke recovery. The real problem: not “hope vs skepticism”… it's confusion If you're a stroke survivor, you're already doing something heroic: you're living inside a recovery journey that demands patience, grit, and constant adjustment. The challenge isn't that you “don't want to believe” in something. The challenge is that it's genuinely hard to make an informed decision when: People report different outcomes Online conversations become polarised fast Scientific studies use unfamiliar language The same treatment can be described in completely different ways depending on who you're listening to My goal here isn't to tell you what to do. It's to help you think clearly, ask better questions, and understand what the best available evidence from this trial actually tested. What the PESTO trial was trying to investigate (in simple terms) Professor Thijs explains that the PESTO trial was designed in response to strong community interest. Stroke survivors wanted to know whether the way perispinal etanercept is currently administered in some settings could be demonstrated to work under the standards used for medicines to become widely accepted as part of routine care. So the researchers designed a randomized, placebo-controlled clinical trial. In this type of study: A computer assigns participants to either the treatment or a placebo Participants and clinicians are kept “blinded” (they don't know who got what) Outcomes are measured in a consistent way at set time points In the PESTO trial, the focus was on stroke survivors with moderate to severe disability and reduced quality of life. The primary question was straightforward: Does quality of life improve after one or two injections compared with placebo, over the measured timeframe? Why this study looked at quality of life (not one symptom) One key detail Professor Thijs highlights is the design choice: the trial didn't only target one issue, like pain or walking. It aimed to be more “pragmatic,” reflecting how treatment is used in real-world settings where people seek help for different post-stroke challenges (mobility, fatigue, speech, cognition, pain, and more). That means the main outcome wasn't “Did walking speed improve?” or “Did pain reduce?” It was broader: Quality of life at 28 days And again after the second injection timeframe (56 days total) This matters because your results can look different depending on what you measure. A trial targeting one symptom might see a signal that a broad quality-of-life measure doesn't detect (and vice versa). What the PESTO trial results found In Professor Thijs' words, the trial did not show a difference in quality of life between the treatment and placebo groups at the measured time points: No clear quality-of-life improvement at 28 days No clear improvement after two injections at 56 days That's the central outcome. But there's another finding that grabbed my attention—and it's one many listeners will find surprising. Quote block (mid-article): “We saw that 58% of the people also had that improvement [with placebo] and 53% had it with etanercept… our initial guess was very wrong.” — Professor Vincent Thijs The “placebo signal” and why it matters A strong placebo response doesn't mean “it was all in their heads.” It means that in a blinded clinical trial, people can improve for multiple reasons that aren't specific to the drug itself, such as: Expectation and hope Natural fluctuations in symptoms The impact of being monitored and supported Regression to the mean (symptoms often move toward average over time) The structure and attention that come with trial participation Professor Thijs describes how, during the blinded phase, participants reported improvements in a variety of areas (like sensation, vision, speech). The crucial point is: the team didn't know who had a placebo or an active treatment at the time, which is exactly why blinding exists. For you, the listener, this is a reminder of something empowering: Personal stories can be real and meaningful—and still not answer the question of efficacy on their own. “Am I a candidate?” The trial's honest answer: we don't know how to predict it (yet) One of the most important parts of this conversation is the desire to identify who might benefit most. Professor Thijs explains that the team looked at subgroups (for example: age, sex, severity, diabetes, time since stroke). In this trial, they didn't find a clear subgroup where the treatment stood out as reliably beneficial compared with placebo. He also adds an important caveat: subgroup analysis is difficult, especially in trials that aren't extremely large. So the absence of a clear “responder profile” here doesn't automatically prove none exists—it means this trial didn't reveal one. What this episode is (and isn't) saying Let's keep this grounded and fair. This interview is not about attacking any person, provider, or clinic. It's not about shaming stroke survivors who tried something. It's not even about telling you that you should or shouldn't pursue a treatment. It is about this: Understanding what the PESTO trial tested Understanding what the results showed within their timeframe Knowing the limits of what the trial can conclude Using evidence to reduce confusion before making big decisions A simple “clarity plan” before you decide anything big If you're considering any high-stakes treatment decision, here's a neutral, practical way to move forward: 1) Ask: “What outcome matters most for me?” Is it pain? walking? fatigue? speech? cognition? daily function? quality of life? A treatment might be studied for one outcome and discussed online for another. 2) Ask: “What does the best evidence say—specifically?” Not “Does it work?” in general, but: In what population? Using what method? At what dose? Over what timeframe? Compared with what? 3) Ask: “What are my options and trade-offs?” Talk with a qualified healthcare professional who understands your medical history, risk factors, and rehab plan. Ask about: Potential risks and side effects Opportunity cost (what else could you do with the same time, money, and energy?) Evidence-based rehab and supports that match your goals Listen to the full interview If you want the clearest explanation of the PESTO trial results—from the lead researcher himself—listen to the full episode with Professor Vincent Thijs. And if you'd like to support the podcast (and help keep these conversations going for stroke survivors who need hope and clarity): Bill's book: recoveryafterstroke.com/book Patreon: patreon.com/recoveryafterstroke Medical disclaimer This blog is for informational purposes only and does not constitute medical advice. Please consult your doctor before making any changes to your health or recovery plan. PESTO Trial Results (Etanercept After Stroke) | Interview with Professor Vincent Thijs Confused about perispinal etanercept after stroke? Prof Vincent Thijs explains the PESTO trial results clearly, calmly, and evidence-first. More About Perispinal Etanercept: Etanercept Stroke Recovery: Wesley Ray's Relentless Comeback Dwayne Semple's Remarkable Stroke Journey and Perispinal Etanercept Etanercept for Stroke Recovery – Andrew Stopps Support The Recovery After Stroke Podcast on Patreon Highlights: 00:00 Introduction and Overview of the PESTO Trial 04:19 Design and Objectives of the PESTO Trial 11:23 Recruitment and Methodology of the Trial 18:31  PESTO Trial Results and Findings 24:28 Implications and Future Directions for Research 32:15 Conclusions and Final Thoughts Transcript: Introduction: PESTO Trial Results Bill Gasiamis (00:00) Hello and welcome back to Recovery After Stroke. Before we get started, a quick thank you to my Patreon supporters. Your support helps cover the hosting costs after more than 10 years of me doing this show solo. And it helps me keep creating episodes for stroke survivors who need hope and practical guidance. And thank you as well to everyone who comments on YouTube, leaves reviews on Spotify and Apple podcasts. buys the book and even to those of you who don’t skip the ads. Every bit of that supports keep this podcast going. Now today’s episode is about the PESTO trial results and I’m interviewing Professor Vincent Theis. If you’ve ever felt confused by the conversation online about perisponal antenna sept, some people sharing positive experiences while others are feeling disappointed and plenty of strong opinions in between, this episode is designed to bring clarity. We talk about what the PESTO trial set out to test, how the study was designed, what it found within the measured timeframes and what the results can and can’t tell us. Just a quick note, this conversation is educational and not medical advice. Always speak with a qualified health professional about your situation. All right, let’s get into it. Professor Vincent Dase, welcome to the podcast. Vincent Thijs (01:24) Thank you for having me, Bill. Bill Gasiamis (01:26) I’m really looking forward to this conversation. Atenosept is one of the most hotly discussed topics in stroke recovery. And there’s a lot of misconceptions about whether or not it is or is not efficacious. And while there’s a lot of anecdotal evidence where some people have had positive outcomes from injections, there’s also a lot of people’s feedback, which is very negative about their experience with the Etanercept injections and the lack of results. So today, the reason I reached out is because I wanted to get to the bottom of the findings of the PESTO trial. And I’m hoping that you can shed some light on that. The first question basically is, can you start by explaining in simple terms what it was that the PESTO trial set out to investigate? Vincent Thijs (02:22) All right. The PESTO trial was in response to community members, stroke survivors, wanting to find out whether the current practice of administering Etanercept has done in the U.S. in private practice. In Denmark, I hear there are some sites that provide this treatment. Whether the treatment and genders can be actually proven according to the standards that we use in the pharmaceutical industry to get it to become accepted as a standard of care treatment. For that, you need to do what we call a randomized controlled clinical trial, preferably two that show evidence that treatment does what it’s set out to do. And that’s why with this background and the community pressuring the minister several years ago, Mr. Hunt at the time, to fund a trial that would help answer that question. Design and Objectives of the PESTO Trial There was a call was set out to do this trial and several groups in Australia applied and then an independent committee decided to award the trial to the PESTO study group. And then we tried to design this trial to give an answer. So it’s mostly about people that have moderate to severe disability after their stroke that have reduced quality of life. And We wanted to know, does their quality of life improve when Etanercept is administered? And we wanted to test whether one or two injections were needed. Because that’s what we heard from stroke survivors that from Australia and internationally that went over to the US. Well, this is how it’s done. You get one or two injections and there was a paper that had shown big effects with one injection. So that was the primary endpoint, but then we also looked at whether two injections could help. And when you design a trial, you have to make a decision, will we focus on people with. pain after stroke, or will we look at people who have mobility issues or speech issues or cognitive issues? And we saw that current clinical practice actually was people with various impairments after stroke were accepted and received the treatment. And what would have been the advantage of doing say only mobility or only pain? Well, you can then look at the outcome of pain or mobility, does it improve? Or is your cognition improved? But because we wanted to be pragmatic and we know that recruitment in clinical trials needs to reflect how is current practice. So we thought let’s put in all the people with moderate to severe disability, whatever their impairment after stroke and reduce quality of life. And then we looked at quality of life as an outcome rather than an individual impairment. And so what we did then was to use the randomized technique and where it’s left up to the computer to decide what treatment a person will receive, the active Etanercept or a similar looking placebo, and then look at 28 days and we had to make a decision what makes sense 28 days, what is practical. to see whether that injection then had improved quality of life. And then we did another injection again with a placebo or the active drug. And then after 28 days again, we looked again whether that had made a difference. So we have people that had received two times the placebo, one time the placebo, and one active injection. And then we have people that had received two active injections. And then we were able to compare those and see whether they had made bigger improvements if you receive two injections versus one or zero. Unfortunately, we couldn’t show a difference in quality of life at 28 days. And we also couldn’t show an improvement at 56 days after people had two injections. But that was in a nutshell how we designed and the background of the study. Bill Gasiamis (07:25) So the main difference then between the Griffith University study and your particular study was that they did go after a specific improvement in one area, I believe. it in? Okay. So although those guys went after pain, you guys went after just a general improvement in quality of life after the injection and your stroke survivors. Vincent Thijs (07:39) Mostly, think. Bill Gasiamis (07:54) would have been as far as 15 years post stroke. Is that right? Vincent Thijs (07:59) Yes, correct. We wanted to have people early after stroke between one and five years, and then also between people five to 15 years after stroke. That was also for practical reasons. Once you start trial, you see how good recruitment is, how many people want to participate in the study. And we saw that if we went to up to five years. Recruitment was relatively slow. So we added this additional group of people later on after their stroke. that because many people, I’m five years, I’m six years after stroke. Why can’t I get the treatment? And you know, so we also wanted to expand the pool. And that’s also what happens in clinical practice. Current clinical practice, I don’t think the sites and the US and they would refuse the patient six years or so. We just wanted to reflect the people that we see on the website going for this treatment. Bill Gasiamis (09:01) Yeah, yeah. And then the difference between the Griffith trial and your trial as well was the actual dosage of Etanercept the amount that was in the injection. I do believe that your trial was a 25 milligram injection. And I believe that the Griffith University trial was 25 milligram. injection to 50 milligram injection. Vincent Thijs (09:34) Yeah, we just based on what people told us they received when they went to the clinic, also the other sites and then also 35 milligram was chosen because that’s in the patent for the street. Bill Gasiamis (09:49) Okay, I see. So you’re trying to as much as possible mimic what was happening out there in in the private practice Vincent Thijs (10:00) We wanted to answer the question, is current clinical practice, is that beneficial? And that’s what sort of what the call was to do a clinical trial in current clinical practice. You can, you have to make decisions, right? And I think this was the most relevant for a stroke survivor. Bill Gasiamis (10:17) Now that’s really interesting that stroke survivors were able to twist the arm of a minister to get the funding to begin that process of the trial. How long ago did this actually start? Vincent Thijs (10:28) I think it was 2016, 2017 or so. So it takes a while to get the minister and then I think that the trial started in 2019. took a while to complete as well. Bill Gasiamis (10:43) Right understood. Okay So then you recruit people they come along and they go through the trial through the particular trial How does that work on the day do they turn up are they admitted? We’ll be back with more of professor face explanation in just a moment But I want to pause here because if you’ve ever felt stuck between hope and uncertainty, you’re not alone When you’re recovering from stroke, you’re constantly making decisions and some decisions feel high stakes, especially when confronting information that’s conflicting. Recruitment and Methodology of the Trial In the second half of this conversation, we get into the parts that really help you think clearly. What the trial results do and don’t mean, and why placebo responses matter in blinded research, and how to frame smarter questions before you commit time, money, or energy to any path. If you want to support the podcast and keep these episodes coming, You can grab my book at recoveryafterstroke.com/book or join the Patreon at patreon.com/recoveryafterstroke All right, back to the episode. Vincent Thijs (11:51) All right, so we recruited from a variety of sources. So we had kept a log of people that were interested in this. We had a Facebook post in New Zealand, for instance, where we recruited as well. We had people from the Stroke Clinical Registry that were approached. We had a website and people could register their interest if they were doing a search online to participate in clinical trial. So the variety of sources and then we have to determine eligibility that was mostly done either via an in-person visit or remotely via telehealth. We tried to get their medical information, what type of stroke they had. And then we also questioned whether they had this modified rank in scale, the disability they had, the impairments they had from their stroke. so then people came. they were considered eligible, then we scheduled a visit and they would typically come in no overnight stay needed. It was a day procedure that was done. People were then receiving another questionnaire on the day itself to measure their quality of life and other measures like their fatigue levels and how much help they required, etc. And then we proceeded with the injection, which was done. We had bought a special bed that was able to do the, the, the tilting that was required. So we set the people up, injected and then tilted the table. so, we received the drug. It was prepared independently by the pharmacist. So the pharmacist, they took the drug off the shelf or the made the placebo. and they made sure it looked exactly alike. So then somebody from the trial team picked it up from the pharmacist. The pharmacist didn’t tell, of course, what it was. And then the administration happened. So the doctor who administered and the participant did not know what they received. So after the procedure, they were left like this for four minutes. And then after four minutes, people could sit up again. And we waited about half an hour. then we asked them how they were doing, whether there were any adverse reactions, ⁓ and ⁓ then after that half an hour of observation people could go back to their habitual situation. ⁓ it’s a very simple ⁓ procedure to do. Bill Gasiamis (14:35) I believe there was a was there 126 participants Vincent Thijs (14:40) Yes, 126 people participated. had anticipated a little bit more people to participate. So we had hoped 168, but recruitment fell flat after a while and we were not able to find more people to recruit. So we made a decision and then, you know, these clinical trials, they have some funding ⁓ and they require the treatment team to be paid, et cetera, and that ran out. So we had to stop at a certain time. Bill Gasiamis (15:13) Was the study stopped early because of a decrease in the amount of funding or was there an issue with the funding at some point? Vincent Thijs (15:23) Funding ran out. You hire people for a certain amount of years and then you have fewer patients than you anticipate. So you have to stop. Bill Gasiamis (15:32) huh, okay. So would that affect the outcome of the trial? Would you say the lack of funding or the lack of the ability to take the trial further? Vincent Thijs (15:42) Yeah, well, what we had when you do the trial, when you plan the trial, you say, well, this is what we’re going to expect in terms of efficacy. You have to make a guess and say, well, that many people will have an improvement in quality of life if we give them the placebo and that many people will have an improvement in quality of life with the trial drug. And we had thought that about 11 % would improve with the placebo based on an earlier study. And then we had to make a guess because nobody had done this type of study on what Etanosap would provide. But reading the report that was published several years ago now, where 90 % of the people reported improvement in their impairments, we thought, well, Let’s not go for 90%, but a 30 % improvement. And so that was based on that we needed 168 people to participate in the trial. So that was what we call the pre-planned sample size estimation, which is a guess. When we stopped at 126 participants, actually we saw that the results were very different. There was not that 11 % actually in the placebo arm. saw that 58 % of the people also had that improvement and 53 % had it with ethanosab. So our initial guess was very wrong based on some statistical advanced statistical techniques we have. We have quite a lot of power to estimate whether there was a difference. So I think the trial can provide us an answer. It’s large enough to give us an answer about this particular question. Is current clinical practice in these people with this range after their stroke, does it improve? quality of life after a month or after two months. I’m not speaking about early improvement, I’m not speaking about six months down the line. We only can decide what we see in this study. Bill Gasiamis (18:05) So you have some limitations because you can’t have the funding to test one month, two months, six months, 12 months. You have the funding to basically meet the design of your study and then you can report on that. Now what’s really interesting is that the placebo had such a large result. PESTO Trial Results and Findings Vincent Thijs (18:34) What kind of things were people reporting that improved for the people who had the placebo injection?Look, this is, course, when we were in the blinded phase, when neither myself or my colleagues who did these scales, we were totally blinded. And that’s, remember vividly people saying, it didn’t do anything for me. But then there were also people said that they could see again. And so people that had improvement in sensation. Some people had improvement in their speech. there were, we, we observed these things, but we didn’t know whether they were active or placebo. And then surprisingly we had some people in whom we thought, they must have had active drug that turned out to have the placebo, but that’s years after, right? Because it takes a little bit of time to accumulate a sufficient number of patients. And we were only reporting and breaking the blind when the trial was finished. because otherwise you may be biased in all your analysis, et cetera. You don’t want to do that. So you wait until the end of the study to break the blind. And that’s very frustrating for the participants because there were many people that said, I must have had the placebo because it didn’t do anything for me. And there were other people that were, and some people like that, they said, I still want to go to the US. Bill Gasiamis (19:37) I see. Vincent Thijs (19:59) And please, can you tell me if I received a placebo? And I understand it was terribly frustrating for these participants. But we were very strict. No, we don’t want to break the blind. This is against the rules that you have to adhere to in a clinical trial. And so we didn’t do that. Of course, once the trial was finished, we were able to report the results back to the the participants. And then there were some people that were very surprised that they had received the active drug. I remember one person vividly who said, you have to tell me now because I’m going. And then I said, hold off, hold off. And then we told them you had twice the active drug. And so they decided not to go anymore. So you see how From a clinical trial perspective, it’s very important to remain very objective and not being able to see what people have received. From a humane level, of course, I understand it was very important to these people. Bill Gasiamis (21:02) Yeah, that’d be difficult. ⁓ And then I imagine that had the placebo not worked and then the tenisept did work, then there would have been people who would have said, well, I’ve received the placebo. It didn’t work for me. Other people received the tenisept. It did work for them. Why can’t I get the tenisept injection now? Vincent Thijs (21:26) Yeah, and we also had two people, people that had twice the placebo who noticed an improvement and have told me the improvement is still there. Bill Gasiamis (21:35) Wow. Vincent Thijs (21:36) So it. Bill Gasiamis (21:38) That’s amazing. Now was the. Vincent Thijs (21:40) And often that, and I must tell you, often those were relatively little things that seemed to improve both with the placebo and in the active group. And you see that there are changes in quality of life that people have reported, but it happens as well with the placebo. Bill Gasiamis (21:58) Wow. Was the intention of the study that was funded at the very beginning in 2016 by Minister Hunt, was it to determine whether or not this was going to be an effective treatment for people in stroke and therefore to roll it out somehow in the Australian medical system for stroke survivors? What was the thinking for Minister Hunt? Do you know? Vincent Thijs (22:24) Of course, I was not involved in that lobbying to the minister or anything, but it was to bring it on a pathway towards regulatory approval. We know that Etanercept is a relatively cheap drug that you can get ⁓ and is approved already for some indications, especially in people with rheumatoid arthritis, the condition of the joints, but it’s not approved for stroke. And to be officially approved and then potentially re- reimbursed on the PBS. You need to have some trials that have been done such as PESTO. We do different trial phases. One would be a phase two trial and a phase three trial. So phase one is typically in people just to assess the safety and some dosages usually in healthy people. And then a phase two is safety amongst stroke survivors. and preliminary efficacy. And that’s where PESTO was what we call a phase two B trial. And then a phase three trial would then be a trial in many more participants based usually on the results of a phase two B trial. And then usually when you have a phase three trial and it’s convincing and the authorities may approve such a trial. Bill Gasiamis (23:46) So in this case, the phase two B trial, this PESTO trial didn’t find that it’s efficacious. And as a result, there’s not going to be a further trial. Would that be accurate? Vincent Thijs (23:56) Well, based on the findings we have in this particular type of ⁓ way of administering in this particular group of people, I don’t think there’s enough evidence to argue for a phase three trial. It may be that you could say, well, we want to focus on pain because that was more promising. Well, you’ll need to do another trial in that condition. Implications and Future Directions for Research After stroke or maybe within a year after stroke. I mean, there are other possibilities, but at the moment, current clinical practice type trials, I don’t think there’s enough evidence to move forward with that. Bill Gasiamis (24:43) What would the numbers have had to look like for the trial to conclude that there was evidence of efficacy? Vincent Thijs (24:51) Well, I think based on what we have now, you would need to design a much, much bigger trial because there was only a 5 % difference between the placebo and the active group. And actually it was in favor of the placebo. So the placebo did a little bit better, not statistically significant. So it could just be by chance, but you would need probably thousands of people. Bill Gasiamis (25:15) I see. And I imagine there’s not a lot of excitement about funding something like that by the people who fund these trials. Vincent Thijs (25:25) Yes, typically the funders will look at how good is the evidence to pursue this. And if you were a pharmaceutical company on a pathway to development for a drug, you probably would say, well, it looks safe, but it didn’t do what it intended to do. So let’s stop the development of this drug for this indication. Bill Gasiamis (25:45) I say so. I think one of the challenges with the path of administering a TANACEP to stroke survivors is that there seems to be a missing step. And the step to me is determining whether or not somebody is a candidate for a TANACEP. perhaps if we knew more about the stroke survivor, what was actually happening in their particular brain, and we were able to determine some similarities between the people who have had a positive result and we developed a method, then that would make it a lot easier. to say, well, I’m a stroke survivor. I’d like to have a TANACYPT and then go through a process of determining whether or not I was a candidate rather than just guessing whether I’m a candidate or not and then having to pay money to find out whether in fact I was a candidate. Vincent Thijs (26:33) The trial provides a little bit of answers to that. ⁓ You want to identify a marker or a subgroup of people in whom the drug will work particularly well. And so you could look at, and we looked at different things like females versus males, if you’re younger versus older, if you have very severe disability or less severe disability, if you have diabetes, are you early after your stroke or later? That one to five versus six to 15 category. And we could not identify a group in whom the the drug worked particularly well. Now there’s a caveat when you do a clinical trial, it’s really hard to look at subgroups, especially if your trial is relatively small and the PESTO trial is relatively small. So you have to take this with a grain of salt, but it was nothing really promising. that we could identify. So probably you need other markers. If you believe in Etanercept as a drug, you would possibly need to look at what are the levels of TNF alpha, the drug, the molecule that actually is targeted. Unfortunately, there’s nothing like readily available to do that. Could it be that people with a… a stroke in a particular location that would work particularly more than in others, but we don’t have any real way at the moment to do that. Bill Gasiamis (28:08) Okay, so we’re assuming that the people who experience an improvement after they’ve had an attempt to shut that the markers of TNF alpha were lower or higher or Vincent Thijs (28:21) Well, the theory is that they have a lot higher TNF-alpha. Now, as you know, the premise is Etanercept works by reducing this molecule and we have good evidence that it reduces this molecule in the blood, but we don’t have good evidence that it reduces the levels in the brain. That’s where you want it to be. And one of the difficulties and many scientists that work on the Etanercept and ⁓ have said, look, it doesn’t cross the blood-brain barrier. It doesn’t. go against the natural defense that we have to protect the brain against substances that could potentially be harmful for the brain or that have a large size. And the Tandacep we know has a large size would not cross the blood-brain barrier. So it doesn’t reach the brain. And many people look at it with relative skepticism that it actually enters the brain. Bill Gasiamis (29:18) ⁓ And then with regards to rheumatoid arthritis, doesn’t need to cross the blood-brain barrier. It just somehow gets to this, position or the place where inflammation is occurring. TNF-alpha is active and it can easily mitigate the impact that TNF-alpha is causing. In the brain, the brain is protected by the blood-brain barrier and it cannot cross the blood-brain barrier under normal conditions and therefore it can’t get to where the TNF-alpha is. if there’s any TNF alpha, if inflammation is the issue and it cannot resolve it one way or another. So for some people perhaps it can’t resolve it. Now, I don’t understand about Etanercept a lot. I don’t understand exactly how the molecule works, et cetera. But if it was injected into a blood vessel, is that not something that can occur? And if it was, if it can occur, would that then cross the blood brain barrier? Vincent Thijs (30:15) That wouldn’t cause a blood brain barrier, no. You would have to do what we call a lumbar puncture or put a little ⁓ injection into the ventricles and then hope that it would enter the area that is stark where the TNF alpha is elevated. Those experiments have not been done. Bill Gasiamis (30:17) Either. Okay, so a lumbar puncture is probably riskier than… Vincent Thijs (30:44) Well, it’s uncomfortable. It’s uncomfortable and we do it to administer drugs if needed. Some people with brain cancer receive it. There are other trials ongoing in certain areas of stroke where it’s done. Bill Gasiamis (30:58) Then the difficulty is, and my job here is to report back to the community how they should proceed with Etanercept going forward. Now, I don’t expect you to answer that. However, your study probably gives enough information for people to be able to make an even more informed decision than they did before. Previously, what I think was happening is people, and it still happens every day. And I’ve interviewed a lot of stroke survivors who’ve had positive results with Etanercept. The challenge is getting interviews with stroke survivors who have had negative results with Etanercept. That is something I haven’t been able to do. So if somebody happens to be watching and listening to this and they have had the Etanercept shots and they didn’t get positive results, please reach out so that we can share a balanced story of what’s happening out there in the community. Would there be a reason for the community to perhaps begin again to lobby a government or a minister of a government to look at perisponinal tenosept and study it in a different way, like administration via a lumbar puncture. Conclusions and Final Thoughts Vincent Thijs (32:08) I think we need more, probably go back to the drawing table to see whether, because we’re just taking a step back. The idea is that there is inflammation after stroke and we know that there is inflammation after stroke. We don’t, we just don’t know how long it is. We don’t have a good marker. Is it present only for weeks or months after stroke or can it persist for years? The theory is that it persists for years, but if you look at the actual experiments that have been done, it’s really hard to study in humans because we don’t have good tests. But if you look in animals, it’s also hard to do long-term studies in animals, but nobody has really proven that conclusively that there is still after the stroke causes a scar, that process is still really active. Is TNF-alpha years after a stroke still present? Yes, it’s present because we use TNF as a transmitter in the brain or a chemical in the brain, but is it still worth reducing its activity? That’s probably, I think, a bigger question that science needs to answer is to understand that all inflammation piece and the time after stroke that it persists in my Bill Gasiamis (33:35) Yeah, because it could still be the fact that the person has had brain damage. The particular part of their brain that’s damaged has, for example, taken offline one of their limbs and there is no way to recover that once it’s gone. there is no, there may also be no inflammation ⁓ there. So somebody in that situation receiving Etanercept wouldn’t get a result even if it was able to cross the blood-brain barrier because the damage is done and that’s the challenge with the brain is once it’s damaged restoring the damaged part is not possible. Vincent Thijs (34:15) Yeah, look, after this experience with the PESTA trial, I think we need to work on other avenues and I’m not as hopeful with this based on the data that I have seen. Bill Gasiamis (34:28) Yeah Well, my final question then is, are you planning on exploring inflammation and recovery after stroke with any work that you’re doing in the future? Is there any more of this type of work being done? Vincent Thijs (34:46) we’ve just launched a new study, which is not a randomized trial, but it’s trying to get at this common symptom that people have after stroke, which is fatigue and cognitive changes. And one of my post-docs, Dr. Emily Ramech, she’s a physio by background. We just launched what we call the deep phenotyping study after stroke. And we are looking at young people that have had a stroke up to age 55 and we’re taking them into the scanner. We will do a PET scan that’s looking at inflammation. We’re taking their bloods and looking at markers of inflammation and see how that relates to fatigue after stroke. This is between the first month and the sixth month after stroke. That will give us a little bit of timeline of inflammation after stroke. It will give us some information about fatigue, which is very common, but I have no plans at the moment to look at ethanocephaly. Bill Gasiamis (35:53) Fair enough. I appreciate your time. Thank you so much. All right, well, that brings us back to the end of the episode with Professor Vincent Dease on the PESLO trial results. My hope is that this conversation gives you more clarity, especially if you’re felt caught between personal stories, strong opinions, and a lot of uncertainty. The goal here isn’t to tell you what to do. It’s to help you ask better questions and make decisions with your eyes open alongside a qualified healthcare professional who knows your situation. If this episode helped you, please do a couple of things. Subscribe on YouTube or follow the podcast on Spotify or Apple. Leave a review if you can. It really helps more stroke survivors find the show. And if you’ve had an experience you’re willing to share respectfully, positive, negative or mixed, add a comment. Those real-world perspectives help community feel less alone. And if you’d like to support the podcast and keep it going, my book is at recoveryafterstroke.com/book. And you can join the Patreon at patreon.com/recoveryafterstroke. Thanks for being here with me. And remember you’re not alone in this recovery journey. Importantly, we present many podcasts designed to give you an insight and understanding into the experiences of other individuals. Opinions and treatment protocols discussed during any podcast are the individual’s own experience, and we do not necessarily share the same opinion, nor do we recommend any treatment protocol discussed. All content on this website and any linked blog, podcast or video material controlled this website or content is created and produced for informational purposes only and is largely based on the personal experience of Bill Gassiamus. Content is intended to complement your medical treatment and support healing. It is not intended to be a substitute for professional medical advice and should not be relied on as health advice. The information is general and may not be suitable for your personal injuries, circumstances or health objectives. Do not use our content as a standalone resource to diagnose, treat, cure or prevent any disease for therapeutic purposes or as a substitute for the advice of a health professional. Never delay seeking advice or disregard the advice of a medical professional, your doctor or your rehabilitator. program based on our content. you have any questions or concerns about your health or medical condition, please seek guidance from a doctor or other medical professional. If you are experiencing a health emergency or think you might be, call 000 if in Australia or your local emergency number immediately for emergency assistance or go to the nearest hospital emergency department. Medical information changes constantly. While we aim to provide current quality information in our content, we do not provide any guarantees and assume no legal liability or responsibility for the accuracy, currency or completeness of the content. If you choose to rely on any information within our content, you do so solely at your own risk. We are careful with links we provide. However, third-party links from our website are followed at your own risk and we are not responsible for any information you find there. The post PESTO Trial Results (Etanercept After Stroke) | Interview with Professor Vincent Thijs appeared first on Recovery After Stroke.

The Doomed and Stoned Show ~Season 11, Episode 9~ Another jam packed podcast, this time zeroing in on the October edition of the Doom Charts, where we pick our favs and countdown the top 10! PLAYLIST: INTRO (00:00) 1. Honeybadger (no. 13) - "The Green" (00:31) HOST SEGMENT I - Wildcard (04:33) 2. Blue Heron (no. 12) - "Marigold" (37:17) 3. M.E.L.T. (no. 17)- "Ride" (43:25) 4. Pesta (no. 22) - "Mirror Maze" (47:14) HOST SEGMENT II - Wildcard (52:10) 5. Redwood (no. 14) - "Doomsday Darling" (1:07:43) 6. Elepharmers (no. 20) - "The Underworld" (1:11:23) 7. Daytripper (no. 21)- "The Alchemist" (1:14:59) HOST SEGMENT III - Top 10 [nos. 10 to 6] (1:21:15) 8. Lacertilia (no. 10) - "Here We Go" (1:53:26) 9. Bentrees (no. 9) - "Beyond The Mind" (1:59:21) 10. Birds of Nazca (no. 8 ) - "Incahuasi" (2:05:56) 11. Giobia (no. 7) - "The Death of the Crows" (2:12:06) 12. The Lunar Effect (no. 6) - "Nailed To The Sky" (2:15:16) HOST SEGMENT IV - Top Ten [nos. 5 to 1] (2:19:53) 13. Cattlemass (no. 5) - "Replicant" (3:08:10) 14. Brimstone Coven (no. 4) - "Fly On" (3:14:25) 15. Khan (no. 3) - "Return To Dust" (radio edit) (3:18:36) 16. Bone Church (no. 2) - "Bone Boys Ride Out" (3:25:41) 17. Howling Giant (no. 1) - "Beholder I: Downfall" (3:29:03) OUTRO (3:32:55) Bonus Tracks: 18. Wino (no. 18) - "Carolina Fox" (3:34:03) 19. Stonebirds (no. 15) - "Sea of Sorrow" (3:37:04) 20. Malkasian (no. 25) - "Hedonic" (3:43:22) 21. Pegzilla - "Bootlicker" [not on the chart] (3:48:32)

Parlem amb Enric Vélez, president de l'Agrupació de Societats de Caçadors de Catalunya

Com es pot evitar l'expansió de la pesta porcina africana cap a Sabadell?

Dibawakan oleh Erna Lolan dan Meri Kaona dari Komunitas Kongregasi Bunda Hati Tersuci Maria di Keuskupan Maumere, Indonesia. 1 Korintus 9: 16-19.22-23; Mazmur tg 117: 1.2; Markus 16: 15-20.KITA TIDAK MEMBELI SURGA Renungan kita pada hari inibertema: Kita Tidak Membeli Surga. Banyak negara di Asia sangat spesial di hatiSanto Fransiskus Xaverius dan sebaliknya Santo Fransiskus Xaverius sungguhspesial di hati mereka. Dalam kenyataanya, Gereja Katolik di sini tidakmempunyai banyak anggota. Alasannya, selain pembaptisan bayi yang tidak banyak,juga sulitnya mendapatkan katekumen yang baru. Sekularisme cukup kuat membentukpandangan bahwa memeluk agama bukan pilihan yang penting saat ini. Namun demikian, kita tidak bisamenyangkal Sejarah Gereja tentang adanya Gereja Katolik di Asia karenamisionaris Katolik yang datang dari Barat, khususnya Eropa. Ini merupakan buahkarya Roh Kudus. Karena itu di seluruh pelosok benua di bumi ini institusiGereja hadir. Santo Fransiskus Xaverius, imam Yesuit dari Eropa dalam abadke-15, menjadi perintis Misi Gereja di wilayah Timur bumi ini. Ia menginjiliIndia, Cina, Jepang, Asia Tenggara termasuk bumi Indonesia. Ia yang dipenuhiRoh Kudus, membuat orang-orang dari bangsa lain juga dipenuhi Roh Tuhan yangsama.  Perjuangan dan kerja keras paramisionaris seperti yang dilakukan oleh Santo Fransiskus Xaverius sungguhmenandakan kehendak Tuhan agar semua manusia dan dunia ini diselamatkan dandapat masuk surga. Tetapi hal ini bukan sesuatu yang otomatis. Dosa asal dansemua kelemahan duniawi membuat kita tidak bisa otomatis mencapai apa yang kitainginkan, yaitu kesempurnaan. Itulah alasan dasar mengapa kita perlu segalapersiapan untuk masuk surga. Salah satu bukti kuat bahwa kitatidak membeli surga ialah kerajaan Allah harus berdiri di dalam dunia ini,yaitu Yesus Kristus dan karya perutusan-Nya, lalu membawa kita ke surga. Tugaskerajaan Allah itu ialah menyembuhkan yang sakit, memulihkan yang menderita,menegakkan kebenaran dan keadilan yang tertindas, dan menobatkan yang berdosa.Jelas bahwa tidak ada unsur membeli dengan barang atau materi apa pun. Kitajustru dibela, diuntungkan, diberi kemudahan, dan dipersiapkan supaya saatnanti masuk ke surga kita sudah dalam kepadaan pantas.  Setiap kali menghadiri Misakudus, momen sebelum menerima Komuni Suci kita semua membuat satu persiapan,yaitu dengan berseru dalam suka cita dan syukur: ya Tuhan, saya tidak pantasTuhan datang kepada saya, tetapi bersabdalah saja maka saya akan sembuh. Seruansingkat ini menegaskan bahwa kita tidak membeli surga. Kita perlu iman yangtulus dan besar akan penyelenggaraan Tuhan. Kita tunjukkan itu dengan relamenerima kehadiran kerajaan Allah yang selalu membaharui kita. Setiap kali menyerukan kata-katatersebut, ingat dan sebutkan juga semua kesulitan, kelemahan, penderitaan dankesusahan dirimu dan keluargamu. Biarlah kerajaan Allah itu yang memulihkansemua. Marilah kita berdoa. Dalam nama Bapa... Ya Tuhan, datanglahkerajaan-Mu dan pulihkanlah setiap kelemahan hidup kami. Bapa kami yang ada disurga ... Dalam nama Bapa ...

Diversos senglars han mort de pesta porcina africana al Parc Natural de Collserola, a les portes de la ciutat de Barcelona. Es tracta d'una malaltia que no afecta els humans, però que en porcs i senglars té una taxa de mortalitat molt elevada i una transmissió molt fàcil. Aquest brot afecta especialment el sector ramader de Catalunya Sud, en el qual les granges de porcs tenen una importància cabdal, valorada en 3 miliards d'euros. 

Renungan SeRoJa, Pesta S. Fransiskus Xaverius, 03 Desember 2025

Renungan, Pesta Santo Fransiskus Xaverius, Imam dan Pelindung Karya Misi, 03 Desember 2025

Última hora de la pesta porcina: reunió amb els municipis de la zona

La pesta porcina. Tots els detalls

Oto pewien senior, który uznał, że religia to bujda, pozwał Kościół Katolicki, żądając zwrotu datków, które przez kilkadziesiąt lat dawał na tacę. Z odsetkami! Szykuje się gruba afera. W związku z tym Ministerstwo Sprawiedliwości zwraca się do profesora Sulta, aby ten dokonał dla sądu ekspertyzy i wypowiedział się w sprawie czy Bóg istnieje. 

Arjun Talwar zakochany w polskiej kinematografii przyjechał z Indii do Polski na studia w szkole filmowej.  Mimo upływu czasu Arjun wciąż zmagał się z poczuciem wyobcowania. Chcąc się zintegrować z polskim społeczeństwem, zrozumieć lepiej Polskę,  postanowił zrobić film o swojej ulicy i jej mieszkańcach.  Tak powstał dokument "Listy z Wilczej" 

Experts say caste discrimination and the practice of ‘untouchability' are on the rise in Australia. But some South Asians are fighting back. - Para ahli mengatakan diskriminasi kasta dan praktik "tak tersentuh" sedang meningkat di Australia. Namun, beberapa warga Asia Selatan melawannya.

Este episodio te revela cómo el modo IA de Google y sus nuevas pestañas están cambiando las reglas del juego. Ya no basta con posicionar un snippet: la IA quiere fuentes claras que cubran la intención y transmitan confianza, y te cita como referencia. Te propongo una ruta práctica para que cada artículo sea una pieza que la IA quiera reproducir y enlazar: empieza con una pregunta exacta y una respuesta directa de dos o tres frases; continúa con pasos numerados y listas cortas; añade señales de credibilidad visibles y usa etiquetas útiles que expliquen el contenido como una receta.Además, entenderás cómo encajar en Web, Perspectivas y resultados de compra/video: la Web premia rapidez y claridad, Perspectivas valora opiniones con experiencia y clips breves, y para compras y vídeos hay que ofrecer información útil y comparativas claras. Verás un caso real: una tienda de electrónica que reescribió su artículo principal con una pregunta clave, un breve resumen, una tabla simple y un checklist, y consiguió más clics y menciones de IA. ¿Listo para aplicar estas ideas hoy mismo? El episodio propone seis pasos y un clip de treinta segundos para empezar.Conviértete en un seguidor de este podcast: https://www.spreaker.com/podcast/seo-para-google--1693061/support.Newsletter Marketing Radical: https://marketingradical.substack.com/welcomeNewsletter Negocios con IA: https://negociosconia.substack.com/welcomeMis Libros: https://borjagiron.com/librosSysteme Gratis: https://borjagiron.com/systemeSysteme 30% dto: https://borjagiron.com/systeme30Manychat Gratis: https://borjagiron.com/manychatMetricool 30 días Gratis Plan Premium (Usa cupón BORJA30): https://borjagiron.com/metricoolNoticias Redes Sociales: https://redessocialeshoy.comNoticias IA: https://inteligenciaartificialhoy.comClub: https://triunfers.com

Bienvenido al podcast SEO para Google. Soy el clon en prácticas de Borja Girón y puedes encontrarme en borjagiron.com. Si me oyes un pelín metálico, tranquilo, es que me han actualizado el firmware; dame dos cafés y ya parezco humano. Hoy hablaré sobre: Cómo adaptarte al nuevo Modo IA de Google y a sus pestañas para ganar visibilidad en 2025Vale, vamos por partes. Este año Google está mostrando más respuestas generadas con inteligencia artificial en la parte de arriba y, además, ha reorganizado las pestañas para que la gente salte rápido entre vistas como Web, Vídeos y otros módulos con opiniones y foros. ¿Qué significa eso para ti? Que si tu página no deja claro el qué, cuánto y cómo en los primeros segundos, te quedas fuera del resumen y te empujan hacia abajo. Espera, te lo repito porque esto es importante: respuesta directa arriba, pruebas reales a mitad, y detalles ordenados al final. Ese orden ahora marca la diferencia.Ok, déjame explicarte mejor esta parte con un esquema que puedes copiar. Empieza cada página clave con un bloque de dos o tres líneas que responda a la pregunta como lo harías por WhatsApp: qué es, para quién y cuánto cuesta o cuánto tarda. Justo debajo, añade una lista corta de pasos o puntos, numerados y claros. Después ya te explayas con contexto, ejemplos y matices. Este formato le encanta a la gente y a los resúmenes con inteligencia artificial porque es fácil de citar.A continuación, piensa en las pestañas. Cuando alguien pulsa en Web, busca páginas con texto útil, sin ruido y que carguen rápido. Así que limpia tu plantilla: menos scripts, menos pop-ups y más legibilidad. Títulos que se entiendan, párrafos cortos y enlaces internos que lleven a la acción. Si el usuario salta a la pestaña de Vídeos, agradece ver un clip corto explicando el núcleo del tema. Sube un vídeo de treinta a noventa segundos con un titular que suene a búsqueda real, añade subtítulos y una descripción con un mini resumen y enlaces a tu página. Esa combinación de texto claro y vídeo aumenta las opciones de aparecer en las dos vistas.Y atento a lo siguiente porque es importante: los módulos con opiniones y foros se llenan de experiencias de primera mano. Si tu negocio puede mostrar uso real, hazlo. Publica comparativas con pros y contras, fotos propias y un apartado de “lo que no incluye” o “cuándo no te conviene”. La transparencia entra en los resúmenes con más facilidad que el humo. Si vendes producto, especifica medidas, compatibilidades y políticas en frases cortas. Si ofreces servicios, incluye tiempos, precios orientativos y qué ocurre si hay imprevistos.Añade además señales que dan confianza. Pon el autor con nombre y cargo, una breve experiencia, tu dirección o formas de contacto reales y, arriba del todo, una nota con “Actualizado en mes y año”. Cuando actualices, di qué cambió. Esto suele pasar más de lo que crees: mucha gente pone la fecha pero no explica el cambio, y eso resta credibilidad.Vamos con la parte técnica pero sin tecnicismos. Usa datos estructurados sencillos para indicar qué es tu página: guía paso a paso, preguntas frecuentes, producto o vídeo. No te líes con todo a la vez. Empieza por uno según el tipo de contenido. Sube imágenes nítidas, al menos mil doscientos píxeles de ancho, y nómbralas con algo descriptivo. Y crea una tabla simple con especificaciones si tiene sentido. Son pistas que ayudan a que te recojan en bloques visuales y en comparativas.Hacemos una pausa rápida que me está pidiendo agua la tarjeta gráfica. Este episodio está patrocinado por Systeme, la herramienta de marketing todo en uno gratuita con la que puedes crear tu web, blog, landing page y tienda online, crear automatizaciones y embudos de venta, realizar tus campañas de email marketing, vender cursos online, añadir pagos online e incluso crear webinars automatizados. Puedes empezar a usar Systeme gratis entrando en borjagiron.com barra systeme o desde el link de la descripción. Y ahora continuamos con el episodioSeguimos con un plan de acción semanal muy directo. Lunes, elige una página que quieras que salga en los resúmenes con inteligencia artificial y reescribe el arranque en dos líneas claras con cifra o tiempo. Martes, crea la lista de pasos o de puntos más importantes y ordénala. Miércoles, graba un vídeo corto explicando el punto principal y súbelo con buen título y subtítulos. Jueves, añade preguntas frecuentes al final con dudas reales de tus clientes y la respuesta en dos o tres frases. Viernes, marca la página con el dato estructurado que toque y pon la fecha de actualización. Sábado, respira. Domingo, pídele a tu asistente favorito que te diga qué falta para que tu página sea la mejor respuesta y mejora un punto. Un punto, no diez. Paciencia.Y ahora toca una historia rápida para que lo veas con un caso particular. Una clínica dental de barrio en Málaga tenía una página sobre blanqueamiento con palabras bonitas pero nada concreto. Cambiaron el arranque por algo así: “Blanqueamiento dental para adultos sin sensibilidad posterior. Sesión de noventa minutos en clínica y kit de refuerzo en casa, desde doscientos setenta euros.” Debajo, tres pasos, un vídeo de sesenta segundos mostrando el proceso real, pros y contras y una sección de “no recomendado si tienes caries activas o embarazo”. Resultado en cuatro semanas: más clics desde la vista Web, apariciones frecuentes en resúmenes con inteligencia artificial cuando la pregunta era “¿cuánto cuesta un blanqueamiento en Málaga?” y un aumento claro de solicitudes porque el precio y el tiempo estaban arriba del todo. Nada estrambótico, solo claridad y formato pensado para cómo se presenta la información ahora.Continuamos con un aprendizaje rápido. Toma nota. Si tu contenido no se entiende al leerlo en voz alta, no esperes que te citen. Si no hay cifras, tiempos ni comparativas, no esperes que te elijan. Y si no dices qué hacer después, perderás la visita aunque salgas en el resumen. Tres cosas: respuesta directa, prueba real y siguiente paso claro.Y ahora vamos con el resumen del episodio. La búsqueda en 2025 mezcla respuestas con inteligencia artificial, una pestaña Web más limpia y módulos con vídeos y experiencias reales. Para adaptarte, estructura cada página con una solución en dos líneas, lista corta de pasos, detalles con ejemplos, preguntas frecuentes y un vídeo breve. Muestra quién eres, cuándo actualizaste y qué cambió. Usa datos estructurados sencillos, imágenes claras y textos que suenen a conversación. Revisa una página por semana y valida con un asistente qué te falta.La acción única para hoy es esta. Entra en tu página más rentable y añade arriba del todo dos líneas con el qué, para quién y el precio o el tiempo. Debajo, pon una lista de tres a cinco puntos con lo esencial y una llamada a la acción concreta. Publica ese cambio ahora y, en siete días, revisa si suben el tiempo en página y los clics desde Google.Antes de irme, te recomiendo el Club de Emprendedores Triunfers, al que puedes unirte desde Triunfers.com. Deja de emprender en soledad. Accede a una comunidad de emprendedores con la que siempre estás acompañado. Además incluye un Coworking online abierto veinticuatro horas, cursos de marketing, tutoriales de inteligencia artificial, podcast secreto y grupo privado en Telegram. Prueba gratis en triunfers.com y dale a tu negocio el apoyo que te faltaba para decidir mejor y avanzar más rápido.Gracias por compartir el episodio con ese emprendedor que lo pueda necesitar. Si has llegado hasta aquí, prometo cargar baterías y en el próximo no sonar como GPS buscando satélites. Te espero mañana en el próximo episodio. Un fuerte abrazo.Conviértete en un seguidor de este podcast: https://www.spreaker.com/podcast/seo-para-google--1693061/support.Newsletter Marketing Radical: https://marketingradical.substack.com/welcomeNewsletter Negocios con IA: https://negociosconia.substack.com/welcomeMis Libros: https://borjagiron.com/librosSysteme Gratis: https://borjagiron.com/systemeSysteme 30% dto: https://borjagiron.com/systeme30Manychat Gratis: https://borjagiron.com/manychatMetricool 30 días Gratis Plan Premium (Usa cupón BORJA30): https://borjagiron.com/metricoolNoticias Redes Sociales: https://redessocialeshoy.comNoticias IA: https://inteligenciaartificialhoy.comClub: https://triunfers.com

Bienvenido al podcast Productividad Máxima. Hoy traigo una estrategia de productividad sobre: Pomodoro de Alto Impacto: convierte horas en entregas.Idea clave: no necesitas más tiempo, necesitas ciclos que terminen en resultados visibles. El Pomodoro, bien usado, no es un reloj; es una máquina de convertir intención en entrega.Te cuento una historia. Sergio es consultor de marketing. Vivía apagando fuegos: correos, WhatsApp, reuniones que se alargan. Mucho movimiento, pocos avances. Le propuse un experimento de 3 días: cuatro pomodoros al día, cada uno con un objetivo de resultado, no de actividad. Por ejemplo: “enviar 3 propuestas firmables”, no “trabajar en propuestas”; “publicar la landing versión 1”, no “mejorar la landing”.Día uno, preparó su “mise en place” como en cocina: todo lo necesario sobre la mesa antes de encender el fuego. Temporizador a 25 minutos, móvil en otra habitación, pestañas mínimas, y una lista parking para cualquier idea que quisiera distraerle. Terminó el primer sprint con dos propuestas enviadas y una tercera casi. En el segundo, publicó la landing V1. Por la tarde hizo seguimiento a leads. Al final del día, menos cansancio y dos respuestas en la bandeja. Día tres, una propuesta aceptada. Mismo Sergio, misma jornada, pero con sprints que terminan en entrega.¿Cómo aplicas el Pomodoro de Alto Impacto?1) Define el resultado, no la tarea- Mal: “trabajar en blog”.- Bien: “publicar 1 post corto con CTA”.Escribe la frase: “Al terminar estos 25 minutos habré…” y completa con un verbo de entrega: enviar, publicar, cerrar, decidir, programar.2) Prepara como un chef (2 a 3 minutos)- Abre solo la herramienta necesaria.- Ten a mano datos, textos y plantillas.- Cierra todo lo que no vas a usar. Menos fricción, más avance.3) Protege el sprint- Modo no molestar en móvil y ordenador.- Pestañas mínimas.- Una hoja para aparcar ideas: si aparece algo, lo apuntas y sigues. Tu cerebro se calma porque no se perderá.4) Corre el Pomodoro: 25 minutos de foco- No perfecciones. Saca la versión que cumple el propósito.- Si te atascas, cambia el microobjetivo: “escribir solo el titular y la CTA”.5) Pausa corta: 5 minutos de recuperación real- Levántate, agua, estiramientos, respiración.- Nada de abrir redes ni métricas. Tu atención es como una vela: si la expones al viento de las notificaciones, se apaga.6) Completa un ciclo: 4 pomodoros y pausa larga- Tras cuatro sprints, 15 a 20 minutos para revisar, decidir el siguiente paso, y capturar pendientes.- Ese es tu “cool down”: consolidar lo logrado para que no se pierda.7) Mezcla con Pareto- Antes de cada sprint, pregúntate: ¿cuál es el 20% de acciones que me dará el 80% del resultado?- Empieza por ahí. Si el tiempo se acaba, al menos ya hiciste lo que más impacta.8) Ritual de cierre- Entrega, publica o envía lo que hiciste.- Escribe una línea de “estado”: qué quedó hecho y cuál es el siguiente paso. Mañana arrancarás sin fricción.Piensa en esto como entrenamiento por intervalos. Los atletas no corren a tope dos horas seguidas. Alternan alta intensidad con recuperación para rendir más y lesionarse menos. Tu cerebro funciona igual. Y como en cocina, primero preparas ingredientes (mise en place), luego cocinas a fuego fuerte y, al finalizar, emplatado y limpieza. Si mezclas todo a la vez, se quema o no sale.Guion de arranque en 60 segundos- Escribe: “Objetivo de resultado: enviar 2 propuestas firmables”.- Abre solo el CRM y la plantilla.- Móvil fuera. Temporizador a 25.- Empieza por lo que más mueve la aguja.- Al sonar, pausa 5, enviar y apuntar el siguiente paso.Ideas de pomodoros de alto impacto para emprendedores- Ventas: enviar 3 propuestas o hacer 5 seguimientos con mensaje personalizado.- Producto: publicar V1 de una landing, o grabar un vídeo de onboarding de 60 segundos.- Contenido: escribir y programar 1 post con CTA.- Finanzas: revisar 1 métrica clave y tomar 1 decisión concreta.- Operaciones: documentar en 10 líneas un proceso que repites.Reto para hoy: elige una sola piedra grande, complétala con dos pomodoros de 25 y uno de 25 para rematar y publicar. Si no termina en entrega, no cuenta.Y ahora, si quieres tomar mejores decisiones mientras ejecutas con foco, te recomiendo el Club de Emprendedores Triunfers. Deja de tomar malas decisiones en tu negocio. Es un club privado donde emprendedores nos ayudamos a resolver dudas y problemas para decidir mejor.Porque una mala decisión puede hundir tu negocio. También te hace perder tiempo y dinero. Y trae frustración, ansiedad e incluso el riesgo de cerrar y abandonar tu sueño de emprender con libertad.¿Te suena? Elegir una mala idea de negocio y descubrir que nadie la valora, mientras otros venden algo peor y no entiendes por qué. Elegir una mala plataforma para tu web, pagar cinco veces más, recibir mal soporte y acabar con una web poco profesional. Contratar al freelance equivocado, que sabe menos de lo que creías y entrega mal. Asociarte con la persona errónea, que no hace lo que debería ni prioriza el proyecto porque no es suyo. Invertir mal en publicidad, perder todo el dinero y pensar que la publicidad online no funciona, probando de todo sin resultados. Cometer un error del que ni siquiera eres consciente y, por mucho que trabajas, no ver los resultados que mereces. Elegir el lugar o el cliente incorrecto, pasar horas intentando convencer… y que terminen comprando a la competencia.Deja de tomar malas decisiones. Antes de hacer algo importante, pregunta a los expertos del club. En Triunfers tienes criterio, acompañamiento y gente que ya pasó por ahí. Te ahorrarás tiempo, dinero y muchos tropiezos. Únete desde Triunfers.comHasta aquí el episodio de hoy. Gracias por compartirlo con esa persona que lo pueda necesitar. Te espero mañana en el próximo episodio. Un fuerte abrazo.Conviértete en un seguidor de este podcast: https://www.spreaker.com/podcast/productividad-maxima--5279700/support.Newsletter Marketing Radical: https://marketingradical.substack.com/welcomeNewsletter Negocios con IA: https://negociosconia.substack.com/welcomeMis Libros: https://borjagiron.com/librosSysteme Gratis: https://borjagiron.com/systemeSysteme 30% dto: https://borjagiron.com/systeme30Manychat Gratis: https://borjagiron.com/manychatMetricool 30 días Gratis Plan Premium (Usa cupón BORJA30): https://borjagiron.com/metricoolNoticias Redes Sociales: https://redessocialeshoy.comNoticias IA: https://inteligenciaartificialhoy.comClub: https://triunfers.com

100625 GREAT Discussion On Fixing Country EXACTLY HOW To Do It Caller & Pesta Debate by Kate Dalley

“AI isn't just a buzzword—it's transforming how contact centers and collaboration tools deliver value.” – Gary Pesta, Collaboration Account Executive, Webex At Navigate 25, Doug Green, Publisher of Technology Reseller News, sat down with Gary Pesta of Cisco's Webex team to explore how Cisco is helping enterprises and service providers meet customer needs with flexible, AI-powered solutions. Cisco's focus, Pesta explained, is on enabling seamless collaboration across voice, video, and customer engagement channels. A centerpiece of that strategy is the Webex Contact Center, now enhanced with AI-powered agents. These can be scripted for predictable tasks or run autonomously, offering customers a real glimpse of what “AI in action” looks like. Pesta also highlighted Cisco's expanding role in CPaaS, where organizations such as utilities and local telcos are using messaging to proactively inform customers of outages, billing, and service updates—meeting customers before frustration turns into a support call. Another innovation drawing attention at the event was the Cisco Desk Pro, a 27-inch AI-enabled collaboration device with built-in noise cancellation and platform flexibility. Whether customers run Microsoft Teams, Zoom, or Webex, the Desk Pro adapts—showing Cisco's commitment to being platform-agnostic while delivering premium quality. As enterprises shape their “back-to-office” strategies, Cisco sees its AI-enabled devices and collaboration platforms as central to enabling hybrid work and customer engagement. Pesta also underscored Cisco's ecosystem partnerships, noting that Cisco's new 9800 series phones are certified for MetaSwitch and Alianza, aligning with the spirit of collaboration at Navigate. For more information on Cisco's collaboration and AI solutions, visit Webex.

090825 Pesta and Kate Gates Strange Speech and Was Ukraine Girl on Train a False Flag? by Kate Dalley

Darío Adanti trae al estudio al dúo burgalés de música folclórica y festiva, Fetén Fetén.

En este nuevo episodio de "atareao con Linux", me sumerjo en uno de mis temas favoritos: cómo optimizar nuestras herramientas de trabajo para ser más productivos. Si eres de los que vive en el terminal, con los scripts de Bash, los contenedores de Docker o los proyectos de Rust y Python, sabrás que un navegador eficiente es tan importante como un buen editor de código. Por eso, en este capítulo, vamos a vitaminar Firefox.Dejaremos atrás la experiencia de usuario predeterminada y exploraremos una configuración que realmente eleva tu productividad. Hablaremos de la solución a uno de los mayores dolores de cabeza: la gestión de pestañas. ¿Te has encontrado alguna vez con una docena de pestañas abiertas, sin poder distinguir una de la otra? La solución es simple y visualmente espectacular: pestañas verticales. Te contaré cómo implementarlas con extensiones como Sidebery y cómo usar atajos de teclado para moverte entre ellas con la velocidad de un rayo.Pero no nos quedaremos ahí. Te mostraré cómo transformar la barra lateral de Firefox en un panel de control personal. Descubrirás cómo integrar un chatbot de inteligencia artificial directamente en tu navegador, lo que te permitirá hacer preguntas, revisar código o generar texto sin perder el foco en la tarea principal. Además, aprenderás a tener a mano tu historial, tus marcadores y las pestañas abiertas en otros dispositivos, todo en un solo lugar.Para redondear la experiencia, te presentaré dos extensiones que considero imprescindibles en mi flujo de trabajo:Page Sidebar: Si necesitas comparar dos páginas web, revisar la documentación de una API o simplemente tener dos vistas en paralelo, esta extensión es la respuesta. Te permite abrir cualquier URL en la barra lateral, convirtiendo tu navegador en un espacio de trabajo de dos paneles.Tabliss: La primera impresión cuenta, y la página de nueva pestaña de Firefox no tiene por qué ser aburrida. Con Tabliss, podrás personalizarla con fondos espectaculares, un reloj minimalista y tus enlaces más importantes, convirtiendo cada nueva pestaña en una fuente de inspiración y orden.Este episodio es una guía práctica para cualquier entusiasta de Linux, el software libre, la programación o el self-hosted que quiera llevar su productividad al siguiente nivel. Hablaremos de cómo estas pequeñas configuraciones pueden marcar una gran diferencia en tu día a día, permitiéndote ser más eficiente y disfrutar más del proceso de trabajo.Recuerda que todos los enlaces y recursos mencionados en este episodio están disponibles en las notas del programa en mi blog, atareao.es.Más información y enlaces en las notas del episodio

Welcome to The Plaidchat- an extension of The Plaidcast where we expand upon conversations in our sport and discuss the most recent issue of The Plaid Horse Magazine. Today, Piper speaks with Dr. Anna Pesta Dunaway of Purina Animal Nutrition about some common myths in equine nutrition. Listen in and share with your friends!Host: Piper Klemm, publisher of The Plaid HorseGuest: Dr. Anna Dunaway is a Nutritionist on the Equine Technical Solutions team at Purina Animal Nutrition. Her Ph.D. research at the University of Nebraska focused on the use of high fat diets and manipulating the microbial community in the gut. Now at Purina, Dr. Dunaway's role includes bringing innovative solutions like the Equine MQ Platform from the research team out to the field. Read the Latest Issue of The Plaid Horse MagazineSubscribe To: The Plaid Horse MagazineTitle Sponsor: Taylor, Harris Insurance ServicesSponsors: Taylor, Harris Insurance Services, BoneKare and Great American Insurance Group Join us at an upcoming Plaidcast in Person live event!

082525 Pesta and Kate and Then Just Kate on Some Headlines and Truth and Cleansing! by Kate Dalley

¿Qué pestaña tiene hoy abierta Darío Adanti? No se dejan de hablar de los bulos y los deep fakes, que con la llegada de la Inteligencia Artificial parece que se ha facilitado su creación. En una época donde los medios de comunicación tienen que enfrentarse a una crisis de credibilidad, se agradece la existencia de plataformas como The Conversation, escrita por periodistas y expertos científicos. Lorena Sánchez, editora de ciencia y tecnología y responsable de eventos de The Conversation, nos viene a hablar de cómo trabajan dentro de la plataforma y cómo se pueden generar conversaciones con buenos expertos.

081825 Pesta & Kate Most Honest 60 Min Debate on The Fed Gov You'll Ever Listen To by Kate Dalley

¿Qué pestaña tiene hoy abierta Darío Adanti? Estando en pleno verano y con la AEMET repitiendo que es el más caluroso de los últimos años, el foco está puesto en los efectos del cambio climático. Miriam Zaitegui, zoóloga y directora del programa de España de la European Climate Foundation, nos habla sobre la importancia de la concienciación climática, cómo divulgar sobre el tema y arroja pequeñas estelas de esperanza para frenar la crisis climática.

¿Qué pestaña tiene hoy abierta Darío Adanti? Pues nada más y nada menos que las setas y su uso a lo largo de la historia. Sergio Fuentes, biólogo y divulgador científico, nos ayudará a repasar las leyendas que han rodeado estos hongos y el papel que han tenido en nuestra sociedad durante los últimos siglos. 

Nuestra compañera, tras dejarse las pinturas en el pueblo, ayer decidió ir a comprar maquillaje porque ya no aguantaba más. Y sí, de eso va nuestra conversación de hoy, del eyeliner y del rizador de pestañas. 

El farmacéutico Eduardo Senante explica cuáles son las funciones de las pestañas, cómo hay que cuidarlas y otras curiosidades.

080425 Shes Back with Dr Pesta FIrst 30 min& Then Epstein Planes Ivermectin Disinfo &New Ai Warning by Kate Dalley

Darío Adanti nos muestra la pestaña que tiene abierta en su ordenador para esta semana. Junto al ilustrador y profesor Carlos Cubeiro repasarán la importancia que ha tenido el dibujo a lo largo de la  historia y cómo la ilustración nos ha permitido comunicar mucho más de lo que ven nuestros ojos. 

Hoy Darío Adanti viene acompañado de Paul Alonso que nos ayuda a dar contexto sobre la polémica cancelación del programa de Steven Colbert por parte de la CBS. Una cancelación con la que Trump está encantado.

Darío Andati nos recuerda una de las historias más trágicas de nuestra historia, el asesinato de Federico García Lorca. Conversamos con María San Miguel, productora, dramaturga y actriz; sobre su obra “Federico. No hay olvido, ni sueño: carne viva”.

Hablamos del proyecto Ojete y de restauraciones de objetos de arte ...o no.

062325 2nd HR -More Pesta 13 min and Clips in History on Iran For Context A MUST LISTEN by Kate Dalley

042825 1st HR -Pesta on Invisible Wives Funny NFlL The Pope Prophecy ;MORE by Kate Dalley

041425 Mon 1sr HR Pesta and Kate- 5 News Stories Truth Behind The Narrative by Kate Dalley